Chronic Constipation Market Growth Anticipated: Chronic Constipation Set for Robust Expansion upto 2032, Companies Includes Kissei Pharmaceutical Co., Wecare Probiotics Co., Astellas Pharma

The significant growth of the chronic constipation market is driven by a combination of factors, including advancements in treatment innovations, shifting demographic trends, and evolving therapeutic approaches.
The market for chronic constipation is expected to experience substantial growth from 2019 to 2032, as detailed in the latest report, "Chronic Constipation Market Insights, Epidemiology, and Market Forecast, 2032 [https://www.delveinsight.com/report-store/chronic-constipation-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" by DelveInsight. This growth is driven by advancements in both existing therapies and new treatments scheduled for release between 2023 and 2032, coupled with a rising incidence of the condition.

The report provides comprehensive insights into current treatment practices for chronic constipation, details on emerging drugs in the pipeline, market shares of various therapies, and forecasts for market trends from 2019 to 2032 across the 7MM (the United States, the EU-4 including Italy, Spain, France, and Germany, the United Kingdom, and Japan).

Driving Forces Behind the Chronic Constipation Market Growth

The significant growth of the chronic constipation market is driven by a combination of factors, including advancements in treatment innovations, shifting demographic trends, and evolving therapeutic approaches.

Discover the Anticipated Evolution and Growth of the Market @ Chronic Constipation Therapeutics Market Forecast [https://www.delveinsight.com/report-store/chronic-constipation-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Therapeutic Advancements and Emerging Treatments:

*
Chronic Constipation Clinical Trial Progression: The market is poised for substantial growth, fueled by the introduction of new therapies anticipated to launch between 2023 and 2032. Leading companies such as Kissei Pharmaceutical Co., Ltd., Wecare Probiotics Co., Ltd., and Astellas Pharma Inc., among others, are actively working on developing innovative drugs for potential entry into the market.

*
Chronic Constipation Innovative Therapies: Ongoing research and development efforts are driving the creation of innovative therapies aimed at addressing the symptoms of chronic constipation. Emerging treatments such as Naronapride, Linaclotide, KWA-0711, ASP0456, Tegaserod, AJG555, RM-131, Prucalopride, TD-5108, PEG 4000, Lubiprostone, and others are showing promising results in clinical trials.

Leading Chronic Constipation Companies and Emerging Drugs: Leading companies such as Kissei Pharmaceutical Co., Ltd., Wecare Probiotics Co., Ltd., and Astellas Pharma Inc., among others, are actively working on developing new drugs for potential entry into the chronic constipation market.

Chronic Constipation Therapeutic Landscape: Key therapies for treating chronic constipation include Linaclotide, KWA-0711, ASP0456, Tegaserod, AJG555, RM-131, Prucalopride, TD-5108, PEG 4000, Lubiprostone, Naronapride, and others.

Chronic Constipation Overview:

Chronic constipation is a prevalent digestive disorder marked by infrequent bowel movements and difficulty passing stool. Unlike occasional constipation, which is temporary and typically resolves on its own, chronic constipation is a long-term condition that persists for several weeks or more. Symptoms often include fewer than three bowel movements per week, straining during defecation, and hard, lumpy stools.

Common causes of chronic constipation include:

- Slow Stool Movement: Reduced motility through the colon

- Dietary Factors: Low fiber intake from fruits and vegetables

- Inadequate Fluid Intake: Leading to dehydration

- Lack of Exercise: Contributing to slowed digestion

- Medical Conditions: Such as irritable bowel syndrome (IBS) or other gastrointestinal disorders

- Medication Side Effects: From drugs like opioids or certain antidepressants

- Mental Health Issues: Including stress, anxiety, and depression

- Eating Disorders: Impacting digestive function

Diagnosis of chronic constipation involves a thorough assessment, including:

- Medical History Review: To understand the patient's symptoms and history

- Physical Examination: To identify any physical abnormalities

- Diagnostic Tests: Such as blood tests to rule out underlying conditions, and imaging studies like X-rays or colonoscopy to evaluate the colon's structure and detect any abnormalities

This diagnostic process can be challenging due to factors such as symptom underreporting, overlap with other gastrointestinal disorders, the absence of definitive diagnostic tests, and the lack of standardized criteria. Consequently, a comprehensive evaluation by healthcare professionals is essential.

Management of chronic constipation follows a stepwise approach:

1. Initial Assessment: Identifying and addressing secondary causes and underlying conditions

2. Lifestyle and Dietary Changes: Implementing fiber-rich diets and increasing fluid intake, along with behavioral modifications

3. Laxative Use: If lifestyle changes are ineffective, options include bulk-forming, osmotic, and stimulant laxatives

4. Prokinetic Agents: For persistent symptoms, medications like prucalopride may be prescribed

5. Biofeedback Therapy: Recommended for patients with defecation disorders

6. Surgical Intervention: Considered only as a last resort after all other treatment options have been exhausted

Chronic Constipation Epidemiology Segmentation:

*
According to Yamamoto et al. (2022), an online survey conducted in the US found that the prevalence of chronic constipation was 5.5% based on the Rome III criteria, whereas in Japan, it was 2.1% based on medical consultations.

*
The Comprehensive Survey of Living Conditions in Japan (2017) indicated that constipation is more common in women than men. However, the prevalence among men increases significantly after age 70, with nearly equal rates observed at age 80 and older.

*
Roque and Bouras (2015) found that the cumulative incidence of chronic constipation is approximately 20% in the elderly, significantly higher than in younger populations. Severe constipation is particularly prevalent in older women, occurring at rates two to three times higher than in their male counterparts.

*
Enck et al. (2015) reported that global prevalence rates for chronic constipation vary widely, ranging from 2.4% to 35%, with Germany showing a lower rate of 5%.

*
Shin (2021) highlighted that chronic constipation leads to about 1 million hospital visits annually in the US and forecasted an increase in prevalence due to an aging population.

*
Given the higher rates of chronic constipation in older adults, the prevalence is expected to rise as the global population ages. This trend underscores the growing need for effective management strategies and interventions to address this increasing health issue.

The Chronic Constipation market report [https://www.delveinsight.com/sample-request/chronic-constipation-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

- Total Prevalence of Chronic Constipation

- Prevalent Cases of Chronic Constipation by severity

- Gender-specific Prevalence of Chronic Constipation

- Diagnosed Cases Chronic Constipation

Chronic constipation Marketed Drugs

*
LINZESS (linaclotide): ABBVIE

*
GOOFICE: Eisai Co., Ltd.

Chronic Constipation Emerging Drugs

*
ANJ908 (Pradigastat): Anji Pharma

*
YH12852: Yuhan

Chronic Constipation Market Outlook

Various treatment options are available for chronic constipation, including over-the-counter laxatives, prescription medications, dietary changes, and lifestyle adjustments. With the global rise in chronic constipation cases, the demand for these treatments is anticipated to remain high. Fiber supplements have proven effective in improving functional constipation.

Current literature suggests that osmotic and stimulant laxatives should be the first line of treatment for chronic constipation. Polyethylene glycol (PEG) 3350, known for its substantial osmotic activity, is effective for short-term relief and is available over the counter for occasional constipation.

Linaclotide, marketed as LINZESS, works as an agonist of the Heat Stable Enterotoxin Receptor (Guanylyl Cyclase C). Approved in 2012, it is now available worldwide, including in the US, the UK, France, Germany, China, and Japan, through Allergan Sales LLC.

Lubiprostone, approved by the FDA in January 2006, is used to treat chronic constipation and IBS-C based on clinical studies demonstrating its safety and efficacy.

Prucalopride, marketed as Resolax or Montegrity, is a prescription medication for chronic idiopathic constipation (CIC) in patients who have not found relief from laxatives.

For patients unresponsive to medical treatments, surgical interventions may be considered, including mechanical colon emptying with enema programs for those with slow bowel movements.

Ongoing research is focused on developing novel therapies to address the unmet needs in chronic constipation. Pharmaceutical companies are investing in new treatments aimed at normalizing gut transit, enhancing bowel function, stimulating gut motility, and promoting intestinal secretion.

According to DelveInsight, significant changes are expected in the Chronic Constipation market across the 7MM from 2019 to 2032.

For in-depth insights, access the full report @ Chronic Constipation Market Outlook 2032 [https://www.delveinsight.com/sample-request/chronic-constipation-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-constipation-market-growth-anticipated-chronic-constipation-set-for-robust-expansion-upto-2032-companies-includes-kissei-pharmaceutical-co-wecare-probiotics-co-astellas-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.